HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carlos Fernandez-Del Castillo Selected Research

Carlos Fernandez-Del Castillo Research Topics

Disease

9Neoplasms (Cancer)
01/2024 - 01/2019
6Pancreatic Fistula (Pancreatic Fistulas)
01/2023 - 02/2016
5Adenocarcinoma
11/2023 - 05/2020
5Fistula
11/2022 - 02/2016
3Pancreatic Neoplasms (Pancreatic Cancer)
11/2023 - 01/2022
3Pancreatitis
02/2020 - 12/2004
2Neoplasms, Cystic, Mucinous, and Serous
01/2024 - 01/2019
1Thrombosis (Thrombus)
11/2023
1Surgical Wound Infection
01/2023
1Neoplasm Metastasis (Metastasis)
11/2022
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
01/2022
1Pain (Aches)
01/2022
1Necrosis
02/2020
1Primitive Neuroectodermal Tumors (PNET)
01/2019
1Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2019
1Autoimmune Pancreatitis
01/2019
1Chronic Pancreatitis
01/2019
1Infections
02/2016

Drug/Important Bio-Agent (IBA)

1N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP)IBA
01/2024
1Immune Checkpoint InhibitorsIBA
11/2022
1CarbohydratesIBA
01/2022
1RNA (Ribonucleic Acid)IBA
01/2022
1CA-19-9 Antigen (CA 19-9 Antigen)IBA
01/2022
1folfirinoxIBA
05/2020
1Transcription Factors (Transcription Factor)IBA
01/2019
1HLA-A Antigens (HLA-A)IBA
01/2019
1Biomarkers (Surrogate Marker)IBA
01/2019
1EnzymesIBA
01/2019
1Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
01/2019
1ImmunosorbentsIBA
01/2019
1Hormones (Hormone)IBA
01/2019
1Monoclonal AntibodiesIBA
01/2019
1Octreotide (Sandostatin)FDA LinkGeneric
08/2016
1Indicators and Reagents (Reagents)IBA
08/2016
1TrypsinIBA
12/2004
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
12/2004

Therapy/Procedure

6Pancreaticoduodenectomy
01/2023 - 02/2016
5Pancreatectomy
01/2024 - 01/2019
5Therapeutics
12/2023 - 02/2016
5Neoadjuvant Therapy
11/2023 - 05/2020
2Radiotherapy
06/2023 - 05/2020
1Splenectomy
01/2024
1Antibiotic Prophylaxis
01/2023
1Drug Therapy (Chemotherapy)
11/2022
1Immunotherapy
11/2022
1Precision Medicine
01/2022
1Length of Stay
01/2022
1Patient Readmission
01/2022
1Debridement
02/2020